![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Hetero Labs Limited Hyderabad In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Pioglitazone hydrochloride, Process II, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2017-013 - Rev 01
This Chemical Type CEP, issued on April 05, 2019, remains in force until July 30, 2019, ensuring its reliability within the pharmaceutical industry.
Substance Number 2601 associated with this CEP further emphasizes